Annemiek Broijl

机构：Erasmus MC Cancer Institute · ORCID：0000-0002-0554-8003

发表论文 164 篇 · 总被引 5919 次 · h-index 30

代表论文

• Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network (2025 · HemaSphere · 被引 14)
• Circulating tumor cells predict myeloma outcomes in patients treated with daratumumab, bortezomib, lenalidomide, and dexamethasone (2025 · Blood · 被引 8)
• Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial (2026 · Nature Medicine · 被引 6)
• Circulating tumor cells in myeloma are a compound biomarker for bone marrow high-risk genomic alterations and tumor load (2025 · Blood · 被引 3)
• Daratumumab-bortezomib-cyclophosphamide-dexamethasone for newly diagnosed amyloidosis: ANDROMEDA final survival analysis (2026 · Blood · 被引 2)
• Circulating tumor cells (CTCs) improve risk stratification according to the second revision of the international staging system (R2-ISS) and the ims-IMWG consensus genomic staging (CGS) in newly diagnosed multiple myeloma (NDMM): An analysis from the european CTC consortium. (2025 · Blood · 被引 2)